This clinical trial is focused on studying the effects of a treatment strategy for patients who have experienced a spontaneous intracerebral hemorrhage, which is a type of bleeding in the brain. The study involves the use of a medication called Eliquis (also known as apixaban), which is a type of blood thinner or anticoagulant. The purpose of the study is to evaluate the effectiveness of different treatment strategies, including the use of direct oral anticoagulants like Eliquis, compared to usual care, which may involve avoiding anticoagulation altogether.
Participants in the study will be adults who have a history of a heart rhythm disorder known as atrial fibrillation and have suffered from a spontaneous intracerebral hemorrhage. The study will assess various outcomes over a period of 24 months, including the occurrence of major vascular events, overall survival, and quality of life. The study aims to determine the best approach to prevent future vascular events in these patients.
Throughout the study, participants will be monitored for any major health events, such as cardiovascular or cerebrovascular incidents, and their overall health and quality of life will be evaluated. The study will also look at specific markers of small-vessel diseases in the brain using imaging techniques like MRI. The goal is to find a balance between preventing further bleeding and reducing the risk of blood clots in patients who have experienced a brain hemorrhage.
France 
